Multiple myeloma is an incurable hematological malignancy with a 100% mortality rate that affects a sizeable Chinese population every year. With the introduction of proteasome inhibitors and immunomodulatory agents in China, the median overall survival has seen much improvement in the last decade. The multiple myeloma market of China is expected to expand further over the 2018-2028 period, fueled by the increasing disease incidence and an increasing uptake of targeted agents; most notably that of the recently launched daratumumab and upcoming pomalidomide, due to their potential efficacy in improving PFS in patients, especially in the relapsed/refractory setting. Despite the availability of a number of traditional and novel agents, there will remain a high unmet need for therapies that can significantly improve patients’ PFS and OS, representing an opportunity for new drug developers. Additionally, with the ongoing reforms in the regulatory and access & reimbursement landscape of China, multinational companies are likely to be increasingly incentivized to enter the multiple myeloma market.
- How large is China’s drug-treatable multiple myeloma population, and how will drug-treatment rate change during the forecast period?
- Which are the most commercially relevant drugs in China’s multiple myeloma market and why? What are interviewed experts’ insights into current treatment options? Which clinical needs remain unfulfilled?
- What are the key market access considerations for key therapies in the multiple myeloma pipeline in China? What sales/uptake could they secure in multiple myeloma? What are interviewed experts’ opinions on the key emerging therapies?
- What are the key drivers and constraints in the Chinese multiple myeloma market, and how will the market evolve over the forecast period?
China In-Depth: Comprehensive market intelligence providing world-class epidemiology, keen insight into the China specific access & reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Qualitative and quantitative insights driven by 5 country-specific interviews with thought-leading hematologist oncologists. Supported by survey data collected for this and other DRG research.
Diagnosed incidence of multiple myeloma by disease stage, line of therapy, and geography (urban and rural). Clinically and market relevant drug-treatable populations.
Ten-year, annualized, drug-level sales and patient shares of key multiple myeloma therapies through 2028, based on primary and secondary market research to formulate bottom-up assumptions.
Phase III/PR: 9 regimens; Phase II: 4 agents; coverage of select early-phase products.
- Multiple Myeloma - Geographic Focus: China - Multiple Myeloma | China In-Depth | China
Author(s): Karan Verma, MSc; Akash Saini, Ph.D.; Oliver Blandy
Karan is a Senior Analyst with the China-in-Depth team at Decision Resources Group, where he specializes in disease landscape and forecast reports based on a range of indications and therapy areas and focused specifically on the China healthcare market.
Before joining DRG, Karan was associated with Aranca, a boutique management consulting firm. Prior to that, he was working with Frost & Sullivan, a global healthcare consulting firm, where he was helping clients devise market entry strategies, conducting technology feasibility studies, and doing competitive intelligence for new product development. His prior experience also includes a short KTP program with the University of Southampton, UK. Karan has earned his MSc in Biomedical Engineering from the University of Warwick, and B.E. in Biomedical Engineering from Maharshi Dayanand University, Haryana, India.
Akash is a Principal Analyst in the China In-Depth team at Decision Resources Group. Since 2016, he has specialized in a range of indications including rare disease indications such as DMD, ALS, ITP, IPF, JIA, and retinitis pigmentosa. He has authored Disease Landscape & Forecast reports, Access & Reimbursement reports, and Treatment Algorithm reports based on primary market research and real-world evidence. Prior to joining DRG, Akash was a post-doctoral fellow at the University of Massachusetts Medical School. He has a Ph.D. from the International Centre for Genetic Engineering and Biotechnology, New Delhi.
Oliver Blandy, BSc PGCE MSc, joined Decision Resources Group (DRG) as an Associate Epidemiologist in 2017. He focuses on the epidemiology of cancer.
Oliver holds an MSc from the University of Bristol where he specialized in Nutrition, Physical Activity and Public Health. He also holds a BSc in Chemistry and has a Post Graduate Certificate in Education (PGCE), both from the University of Bristol and taught general science and Advanced Chemistry in high school for two years.
Before joining the team at DRG, Oliver worked as a Research Assistant for Imperial College London where he was the lead for several studies within an NIRH funded research group that investigated healthcare associated infections and antimicrobial resistance.